Teva Sees COVID Sales Correction

Takes Impairment On Japanese Venture And Bolsters Biosimilars Business

 
• By David Wallace
  
Balancing_Coins_Covid
A Q2 decline due to COVID-19 balanced out a spike in demand from Q1 • Source: Shutterstock

More from Earnings

More from Business